Major Results About The Real Effect Of Liraglutide On Reducing Cardiovascular Risk Predictors: Systematic Review Of Clinical Utility
Introduction: Obesity portrays a multifactorial disease and presents a serious public health problem, with an alarming epidemic character. There are about two billion overweight and obese people in the world, and Brazil is in fifth place in the world ranking. This scenario is of concern as overweight promotes increased mortality related to the development of cardiorespiratory and metabolic diseases. Liraglutide (LG) is an analog of the hormone GLP-1.